In the complex ecosystem of American healthcare finance, few entities have polarized the industry as rapidly as HaloMD. Since its inception in 2022, the billing intermediary has transformed from a niche startup into a dominant force in the Independent Dispute Resolution (IDR) process—the federal arbitration system established under the 2022 No Surprises Act (NSA).
To its supporters, HaloMD is a champion for independent medical groups, providing them with the administrative infrastructure necessary to secure fair reimbursement against monolithic insurance payers. To its detractors—including major insurance carriers and fiscal watchdogs—the company is a “leech” that exploits systemic loopholes, artificially inflating the cost of care and burdening the U.S. economy with billions in unnecessary arbitration expenses.
The Genesis of a Dispute Giant
The No Surprises Act was designed with the noble intent of shielding patients from "surprise" medical bills—unexpected charges that occur when a patient receives care from an out-of-network provider at an in-network facility. When providers and insurers cannot agree on a payment rate, the law mandates an IDR process where an independent arbiter decides the final compensation.
HaloMD entered this space in 2022 with a specific value proposition: to help physician groups navigate the technical, time-intensive, and often daunting requirements of the federal arbitration portal. By centralizing the dispute process, HaloMD quickly scaled, now representing over 150 medical groups. Today, it stands as one of the most prolific initiators of arbitration claims in the country.
The company’s growth has been fueled by a formidable track record. HaloMD claims a success rate in arbitration exceeding 90%, with median payouts for its clients reportedly nine times higher than standard in-network rates. While these figures represent a massive windfall for the medical practices they represent, they have simultaneously turned HaloMD into a primary target for litigation and intense federal scrutiny.
Chronology of a Regulatory Flashpoint
- Early 2022: The No Surprises Act goes into effect, creating the federal IDR process to handle payment disputes.
- Mid-2022: HaloMD is formed, aiming to assist providers with high-volume, out-of-network claims.
- 2023–2024: As the backlog of IDR cases grows, academic research from institutions like Georgetown begins to highlight that arbitration is costing significantly more than anticipated—with estimates of administrative and legal costs reaching $22 billion.
- Late 2024: Insurers initiate a wave of lawsuits against HaloMD, alleging that the company floods the system with ineligible, meritless disputes to force settlements.
- March 2026: HaloMD’s chief external affairs officer, Patrick Velliky, publishes research suggesting the NSA has actually decreased total emergency medical spending, a claim that faces immediate backlash from healthcare economists.
The Data War: Is the System Broken or Misunderstood?
The debate over HaloMD centers on a fundamental disagreement over data interpretation. Critics, including the Paragon Health Institute and various consumer advocacy groups, argue that the "torrent" of disputes is evidence of a system being gamed. They point to the fact that providers win more than 80% of IDR cases, suggesting the playing field is tilted in favor of the providers’ representatives.
However, Patrick Velliky argues that the current narrative is based on a fundamental lack of context. In a recent interview with Healthcare Dive, Velliky argued that critics lack a "pre-NSA baseline."
"If I tell you a car costs $35,000 but don’t tell you what it cost last year, you have no way of knowing if it’s an increase or a decrease," Velliky noted. He contends that his internal research shows the NSA has actually saved billions by capping runaway out-of-network costs that were previously unregulated.
Critics, however, remain unconvinced. They argue that Velliky’s reliance on the "Qualifying Payment Amount" (QPA)—a metric reflecting in-network rates—as a benchmark is flawed. Furthermore, they note that his research focuses almost exclusively on emergency medicine, ignoring specialties like neurology or surgery, where arbitration awards have been documented at up to 2,400% of the QPA.
Official Responses and the "Bad Actor" Allegations
The tension reached a boiling point when several large insurers filed lawsuits against HaloMD, accusing the firm of "hijacking" the arbitration process. The allegations are specific: insurers claim HaloMD submits massive volumes of ineligible claims, uses deceptive communication tactics, and relies on misleading data to sway arbiters.
Velliky categorically denies these claims, characterizing them as the reaction of a powerful industry losing its leverage. "Insurers are very, very frequently wrong about eligibility," he stated. "The real reason we have become the target of the plans is that we are the largest player here. We initiate about 21% of annual disputes… They never anticipated that some of the small groups they had been able to bully would suddenly be able to stand up for themselves."
When asked about the "perverse incentives" of the arbiters—who are only paid if a case is found eligible—Velliky admitted that the system is not perfect. He acknowledged that the current structure links financial rewards to eligibility determinations, which he agreed should be reformed to prevent potential bias.
Implications for the Future of Healthcare
The implications of the HaloMD controversy extend far beyond one company. The ongoing conflict highlights the "growing pains" of the No Surprises Act and raises difficult questions for federal regulators at the Centers for Medicare & Medicaid Services (CMS).
1. The Threat of Consolidation
HaloMD argues that their presence is a necessary hedge against corporate healthcare consolidation. By providing independent, mid-sized physician groups with the power to compete in arbitration, they claim to be preventing these groups from being swallowed by private equity-backed hospital systems. If HaloMD were to be dismantled or overly restricted, these independent groups might be forced to sell to larger networks, potentially leading to higher costs for patients in the long run.
2. The Need for Arbiter Oversight
There is an emerging consensus that the IDR process needs more rigorous oversight of the "arbitration entities" (IDREs). If, as research suggests, arbiters who rule more frequently for providers are granted more cases by the system, then the entire premise of "independent" adjudication is at risk. Reformers are now calling for a delinking of arbiter pay from eligibility decisions and a more transparent audit of how these entities reach their final determinations.
3. The Future of "In-Network" Contracting
Perhaps the most significant question is whether the current IDR system creates a disincentive for providers to sign in-network contracts. If a practice can secure significantly higher reimbursement through the IDR process, they have little financial motivation to accept lower, negotiated in-network rates. Velliky argues that providers still prefer the "timely and reliable" cash flow of in-network agreements, but he concedes that if insurers offer rates that are perceived as exploitative, the temptation to utilize the IDR process will remain high.
Conclusion
The battle over HaloMD is a microcosm of the larger struggle to define the "fair price" of American healthcare. While the No Surprises Act has succeeded in protecting patients from receiving the initial, exorbitant bill, it has inadvertently birthed a secondary, high-stakes battleground between the healthcare industry’s administrative gatekeepers.
Whether HaloMD is a "lifeline" or a "leech" may depend on which side of the negotiating table one sits on. However, the legislative path forward seems clear: regulators must address the procedural inefficiencies and perverse incentives within the IDR process before the cost of "resolving" surprise bills exceeds the cost of the bills themselves. For now, the arbitration system remains a high-stakes arena where billions of dollars are won and lost in the margins of federal law, and companies like HaloMD are at the very center of the storm.
